| AVEO: More Open Questions Than Answers - Seeking Alpha |
|
|
Seeking Alpha Earlier this week, AVEO (AVEO) announced topline results from a phase III trial for tivozanib in renal cancer. Although technically the trial met its primary endpoint and could probably lead to approval, results were far from satisfactory. |